NEW YORK (GenomeWeb News) – Eurofins MWG Operon today announced it has acquired gene synthesis firm Entelechon for an undisclosed amount.

Entelechon was founded in 1999 in Regensburg, Germany, and focuses on genomics and proteomics projects "bringing broad experience in the fields of gene optimization and synthesis," Eurofins MWG Operon, the genomics division of Eurofins Scientific, said. The company serves the drug manufacturing industry as well as academic and public research institutes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.